Nanoportal Biotech Introduces ProteanFect™——The World’s First Coacervate-Based Transfection Reagent

Nanoportal Biotech is proud to introduce ProteanFect™, the world’s first coacervate-based transfection reagent. Specifically designed for primary cells and hard-to-transfect cell lines, ProteanFect™ provides a non-viral, non-electroporation, and non-liposomal transfection system utilizing engineered mammalian proteins. This innovative system delivers high transfection efficiency while maintaining an excellent safety profile, empowering researchers worldwide to conduct genetic studies with enhanced precision and ease.

Mechanism of Action of ProteanFect™

ProteanFect™ leverages the natural biological process of liquid-liquid phase separation (LLPS) observed in biomolecular condensates. ProteanFect™ proteins self-assemble with nucleic acids into highly ordered, compact nanoparticles, enabling efficient gene delivery into cells. Once inside, the nanoparticle complex rapidly releases the nucleic acids for gene expression, while the proteins naturally degrade without causing toxicities to the cells.

This breakthrough technology offers superior gene transfer efficiency in primary cells and hard-to-transfect cell lines, providing researchers with enhanced tools for genetic research. Beyond enhancing gene delivery for cell culture, we are expanding our coacervate-based platform to in vivo applications, tackling critical challenges in efficient and safe gene delivery for disease treatment.

We invite researchers and collaborators worldwide to join us in advancing innovation in gene delivery and therapeutic development. Together, we can push the boundaries of genetic science.

For more information, follow us on our official WeChat account or contact our support team: proteanfect@nanoportalbio.com.